Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have liver cancer (HCC) that has spread to other parts of the body, cannot be surgically removed, or is at an advanced stage
• You are in generally good physical condition and able to carry out daily activities with little or no restriction (confirmed by a doctor's assessment)
• Your liver cancer is classified as a specific intermediate or advanced stage (called BCLC stage B or C) — confirm exact stage with trial site
• Your liver is still functioning reasonably well (based on a scoring system called Child-Pugh class A)
• You have at least one tumour that can be measured on a scan
• If you have an active hepatitis B infection, you must have been on antiviral treatment for at least 14 days before joining, with signs that the virus is responding to treatment
• If you have an active hepatitis C infection, it must be well controlled
• Your blood tests show that your organs and bone marrow are working well enough
• You have not previously received any systemic (whole-body) drug treatment for your advanced liver cancer
• Your cancer cannot be treated with surgery or local treatments, or if you did receive local treatment, it was completed at least 28 days before your first study scan

Who may not be able to join:

• You have other serious medical conditions that are not under control
• You have an autoimmune or inflammatory condition that requires ongoing treatment with steroids or other immune-suppressing medicines
• You have a history of another type of cancer (confirm with trial site)
• You still have significant side effects from previous cancer treatment (other than hair loss) that have not improved to a mild level
• You have had a serious build-up of fluid in your abdomen, chest, or around your heart requiring a procedure to drain it within the past 6 months
• You have a history of a weakened immune system disorder or a current serious infection
• You have a history of a condition where the liver causes confusion or brain problems (hepatic encephalopathy)
• You are currently taking high-dose aspirin (325 mg or more per day) or certain blood-thinning medications within 10 days of starting the study
• You are currently taking full-dose blood thinners or clot-dissolving medicines for treatment purposes within 10 days of starting the study
• You have a history of significant bleeding problems or had a serious bleeding episode from the digestive tract within the past 6 months
• You have untreated or incompletely treated enlarged veins (varices) that have bled or are at high risk of bleeding
• Your liver cancer is a specific rare type, such as fibrolamellar HCC, sarcomatoid HCC, or a mixed type involving the bile ducts
• Your cancer has spread to the brain or spinal cord
• You have previously been treated with certain types of immunotherapy drugs (anti-CTLA-4 or anti-TIGIT)
• You have had radiotherapy recently — within 28 days in general, or within 60 days to the abdomen or pelvis (confirm exceptions with trial site)
• You have both hepatitis B and hepatitis C infections at the same time

Important: Always verify eligibility with the trial site directly before applying.